Related Experiment Video

Updated: Dec 23, 2025

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.6K

Evaluation of Lipid Profile in Children Born to Female Transplant Recipients

Beata Borek-Dzieciol1, Natalia Czaplinska1, Monika Szpotanska-Sikorska2

  • 1Department of Neonatology, Children's Hospital, Medical University of Warsaw, Poland.

Transplantation Proceedings
|April 18, 2020
PubMed

Insights

Prenatal exposure to immunosuppressants after maternal organ transplantation did not significantly alter children's lipid profiles. However, abnormal lipid fractions were observed in children exposed to these medications in utero.

Area of Science:

  • Pediatric Nephrology
  • Transplant Medicine
  • Neonatal Health

Background:

  • Assessing offspring health is crucial due to potential nephro- and hepatotoxic effects of maternal immunosuppressants post-organ transplantation.
  • Family planning after transplantation necessitates understanding drug impacts on children.

Purpose of the Study:

  • To evaluate the influence of immunosuppressive drugs on the lipid profiles of children born to mothers who underwent kidney or liver transplantation.
  • To analyze lipidogram parameters in relation to specific immunosuppressive regimens used during pregnancy.

Main Methods:

  • A cohort study comparing 91 children of post-transplant mothers with 91 children of healthy controls.
  • Lipid profiles (total cholesterol, HDL, LDL, triglycerides) were analyzed.
  • Children were grouped based on maternal immunosuppressive regimens: calcineurin inhibitors (CI), CI + glucocorticosteroids (GCs), and CI + GCs + azathioprine (AZA).

Main Results:

  • No significant differences in mean lipid profile levels were found between the study and control groups.
  • Abnormal lipidogram fractions were noted in 31% (CI), 57% (CI+GCs), and 26% (CI+GCs+AZA) of children in the study subgroups.
  • Despite observed abnormalities, no statistically significant differences in lipid disorders were detected between the exposed children and controls.

Conclusions:

  • Prenatal exposure to immunosuppressants following maternal kidney or liver transplantation does not significantly increase the risk of lipid disorders in offspring.
  • Further research may explore long-term lipid health in children exposed to these medications during gestation.
Abstract

More Related Videos

Lipid Exchange Assay in Living Cells08:59

Lipid Exchange Assay in Living Cells

Published on: March 21, 2025

945
Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

377

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
149
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
253
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
133
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
194
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
174
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
120